The Academy of Pharmaceutical Sciences
'Promoting the pharmaceutical sciences'

GTx enrolls first patient in Phase II enobosarm trial to treat triple negative breast cancer.....           Osiris Therapeutics begins phase III trial of OTI-15-01 for treatment of diabetic foot ulcers.....           Tarix Orphan obtains FDA fast track status for TXA127 to treat DMD.....           Bristol-Myers' Daklinza sNDAs gets FDA priority review.....           Johnson Matthey acquires Pharmorphix.....           Baxalta and Momenta announce initiation of pivotal clinical trial for M923, a biosimilar version of HUMIRA.....           McGuff Pharmaceuticals announces FDA approval for Hydroxyprogesterone Caproate Injection, USP.....           AmerisourceBergen to acquire PharMEDium for $2.5bn.....           Otsuka stares down another rival with FDA approval for Alkermes' long-acting Abilify.....           Roche CEO: Big Data needs Big Pharma, and vice versa.....           Drug price hikes a tried-and-true strategy for who's who of Big Pharma.....           Investors cheer as Arena forces out CEO and cofounder.....           AmerisourceBergen snags sterile drug compounder PharMEDium in $2.5B deal.....           Protalex to start Phase Ib trial of immune thrombocytopenia drug in France.....           Bristol-Myers Squibb to pay $14m to settle charges on bribery in China.....           Raptor acquires fluoroquinolone antibiotic Quinsair from Tripex.....           Otonomy gets FDA approval to begin Phase I trial of tinnitus product candidate OTO-311.....           William Campbell, Satoshi Omura and Youyou Tu win 2015 Nobel Prize in Physiology or Medicine.....           Dako announces FDA approval of new companion diagnostic for lung cancer.....           William Campbell, Satoshi Omura and Youyou Tu win 2015 Nobel Prize in Physiology or Medicine.....           Valeant's price-hike strategy goes far beyond two high-profile increases.....           Last-minute deal on drug exclusivity wraps up TPP negotiations.....           Payers want new guidelines, more data before easing access to diabetes' CV star Jardiance.....           Early Gilenya generics now spell trouble for rival MS drugs.....           FDA marketing police most likely to slap pharma for risk-info omissions.....           Vernalis buys US rights of Moxatag from Pragma Pharmaceuticals.....           FDA accepts Sandoz's BLA for biosimilar Etanercept.....           Ultragenyx seeks marketing authorization for Ace-ER tablets in Europe.....           FDA approves treatment combination of Gilead?s Letairis with Tadalafil for PAH.....           Anthera starts Phase 3 study of Sollpura pancreatic enzyme replacement therapy.....           Theralase completes GMP manufacture of second batch of lead drug.....           Karo Bio acquires OTC products manufacturer Swereco.....           UPDATED: Merck's Keytruda snags FDA approval for NSCLC, but label is narrow.....           Neon Therapeutics secures $55m to develop neoantigen-based cancer immunotherapies.....           Pharmalink raises funds to advance Nefecon development to treat kidney disease.....           FTC weighs in on Mylan case, saying generics tweaking may be anticompetitive.....           Novartis targets Amgen's Enbrel with second biosimilar app.....           Ackman's fund takes a beating on Valeant pricing worries.....           Analyst sees big things for Allergan, Amgen despite slow growth in China and biosimilar pressures.....           Pfizer adding dozens of jobs at Ireland plant that was slated to close last year.....           Glaxo's consumer health CEO lays out blueprint for margin turnaround.....           Merck's Keytruda snags FDA approval for NSCLC, but label is narrow.....           FDA approves Bristol-Myers Squibb's Opdivo (nivolumab) + Yervoy (ipilimumab) regimen.....           Santhera Pharmaceuticals launches Raxone in Germany.....           Daiichi Sankyo expands TaNeDS collaborative drug discovery program in Europe.....           Teva agrees to acquire Rimsa for $2.3bn.....           Biohaven and FCCDC form alliance in early stage drug discovery research.....           BioMarin pledges up to $588M to Merck KGaA in rare-disease land grab.....           PTC Therapeutics gets EMA validation for Translarna cystic fibrosis drug.....           Dompé and Omega Pharma sign OTC product range marketing deal.....           New data shows sustained long-term efficacy of OFEV (nintedanib).....           EMA releases draft guideline for public consultation to accelerate antibiotics development.....           Symplmed, PuraCap Pharmaceutical team up to distribute new EpiCeram-L Lip Care.....           Merck to return Kuvan drug rights to BioMarin Pharmaceutical.....           Genzyme opts into Alnylam's ALN-AT3 hemophilia program.....           Ferring to commercialize Apricus' Vitaros ED cream in Latin America.....           Novartis stacks up more data for lucrative Cosentyx expansion.....           U.K. patient group demands government override Roche's Kadcyla patents.....           Express Scripts: Strict prior-auth moves keep a tight lid on PCSK9 sales.....           Teva beefs up in emerging markets with $2.3B Rimsa buyout.....           Bristol-Myers wins $256K nod for Opdivo-plus-Yervoy in melanoma.....           BioMarin pledges up to $588M to Merck KGaA in rare-disease land grab.....           Vetter to invest EUR300m to upgrade manufacturing facilities.....           GSK exercises option for inhaled therapeutics from Liquidia Technologies.....           Aspen Park acquires rights of oral drug to treat castration resistant prostate cancer.....           GlaxoSmithKline Pharmaceuticals acquires Novartis? vaccines business.....           CADCA raises awareness of dangers of prescription (Rx) drug and OTC cough medicine abuse.....           Teva wins approval for COPAXONE to prevent relapse of multiple sclerosis.....           EC grants orphan drug designation to Zafgen's beloranib to treat craniopharyngioma.....           UbiVac forms collaboration with Johnson & Johnson Innovation.....           Corvus Pharmaceuticals closes $75m Series B Financing.....           GTx enrolls first patient in Phase 2 clinical trial of enobosarm in ER+/AR+ breast cancer.....           Accelerator secures $11.7m in new investment commitments.....           Illumina introduces TruSight Tumor 15 panel.....           Vitae starts second part of Phase 1 study of VTP-43742 in psoriatic patients.....           New Hampshire AG launches investigation into opioid marketing.....           How can Pradaxa, Xarelto and Eliquis finally unseat warfarin? Safety data, analyst says.....           Not done yet, Hillary Clinton airs pharma-focused ad starring Turing CEO.....           Merck KGaA counts on Latin America to power consumer-health future.....           Roche poised for MS coup with PhIII success in progressive disease.....           UPDATED: Novartis falls short in controversial IPR process as board nixes Gilenya patent.....           Mesoblast's MPC therapy trial reports better cardioprotective effect.....           Researchers develop brain prosthesis to help memory loss patients.....           Sun Pharma starts tender offer to buy InSite Vision.....           Astellas Pharma, Chromocell partner to develop neuropathic pain therapies.....           Intrexon, ZIOPHARM partner to develop immunotherapies to treat GvHD.....           US federal judge enters permanent injunction against Sunset Natural Products.....           Study finds maintaining healthy DNA delays menopause.....           Novavax secures grant to support RSV F vaccine development.....           Pfizer CEO sees no real future for Clinton's drug-pricing proposals.....           Citing cost, top doctors back limits on PCSK9 cholesterol fighters.....           UPDATED: Allergan's H2 looks lighter without generics, but 10% growth on tap for 2016.....           Who's most at risk if the U.S. cracks down on prices? Gilead, Celgene top the list.....           Eli Lilly and Sanofi settle Basaglar insulin product lawsuit.....           PCORI approves $83m for hepatitis C and other studies.....           Intrexon, ZIOPHARM partner to develop immunotherapies to treat GvHD.....           Ablynx starts Phase III study of caplacizumab to treat acquired TTP.....           NYBC, Howard and Abby Milstein Foundation to advance use of specialized stem cell lines in regenerative medicine.....           Marina Biotech and Hongene Biotechnology sign license deal.....           UPDATED: Sorry, Celgene, patent board says. Bass can challenge your IP, and profit, too.....           CHMP recommends Novartis' Entresto heart failure medicine for EU approval.....           Amgen receives CHMP positive opinions for two new blood cancer treatment options.....           PeptiDream and Teijin Pharma sign peptide discovery collaboration deal.....           Novartis unveils results of Phase III pivotal study of Afinitor.....           Health Canada approves Bristol-Myers Squibb's immunotherapy Opdivo (nivolumab).....           Merck and Pfizer secure FDA orphan drug designation for avelumab.....           Vtesse starts phase 2b/3 clinical trial of VTS-270 to treat NPC disease.....           How much more does the U.S. pay for drugs? Up to 10 times more, report says.....           Novo combats talk of insulin price war with 'moderate premium' on brand-new Tresiba.....           Valeant CEO defends price hikes, business model in letter to worried employees.....           Note to Depomed shareholders: Let Horizon call its meetings, ISS advises.....           Sanofi patent deal lets Lilly roll out a Lantus biosim in U.S. next December.....           Don't count Merck's Keytruda out in lung cancer fight with BMS' Opdivo.....           Shkreli-shaming spills over onto Valeant as Dems call CEO to account for price hikes.....           Sorry, Celgene, patent board says. Bass can challenge your IP, and profit, too.....           European Commission approves Praluent anti-cholesterol drug.....           RSS NEWSFEED....
Welcome to
The Academy of
Pharmaceutical Sciences
The Academy of Pharmaceutical Sciences (APS) is the UK-based professional membership body for Pharmaceutical Scientists.

We represent individuals and organisations from around the globe, throughout their development, in the delivery of excellence in the Pharmaceutical Science sector.
Recent meetings

6th APS International PharmSci Conference
7-9 September 2015 - Nottingham

Exploring The 6Th APS International PharmSci Conference - A Hugh Success…

An overview from Bill Dawson, APS Chair

The flagship Academy conference was a huge success, building on its previous strengths on its return to the East Midlands Conference Centre in Nottingham. The balance between academia and industry was maintained and many young pharmaceutical scientists had their first opportunity to present either poster or podium presentation which is a major strength of PharmSci.


APS Inhaled Product Development Workshop
11 & 12 June 2015 - Loughborough

The purpose of this workshop was to provide an overview of the basics and fundamentals of aerosol science and the broad spectrum of scientific disciplines involved in the process of inhaled product development. This workshop was aimed at helping scientists new to the area to understand the development area in which they work and to put their role into context. It introduced them to the ‘language’ of product development to facilitate involvement in project teams or understand customer needs.


Latest News
APS Stimulating antimicrobial innovation
National Heart & Lung Institute (NHLI), London Thursday 22nd October 2015. A one day meeting focussing on recent and current innovation in antimicrobials will be held on Thursday 22nd October 2015 at the National Heart and Lung Institute, Imperial College, London organised by the APS Microbiology and Anti-infectives Focus Group. Background to the Meeting: The pipeline of new antimicrobial agents is critically stagnant with most major pharma players having limited activity in the antibiotics arena over the past three decades. This meeting aims to capture the cutting edge of the antimicrobial innovation in the UK, to understand the barriers to antibiotic discovery, examine innovation ‘hotspots’ in the UK and highlight developments in the current funding landscape for antibiotics discovery and innovation. The purpose and aims of the APSGB Microbiology and Anti-Infectives Focus Group is to provide a forum for the discussion of all aspects of microbiology and anti-infectives research and development in the pharmaceutical industry and academia, to underpin the importance of microbiology to the pharmaceutical sciences and innovation, and to provide continuing education, resources and a voice for pharmaceutical scientists in the challenging area of antimicrobials development. Meeting Format: We are delighted to announce an exciting programme of high profile speakers who are leading experts and opinion formers in the fields of antimicrobial resistance, antibiotic discovery, novel therapeutic target development and representatives of academia, the pharmaceutical industry, SMEs and the major UK funding bodies. Key Opinion Leader Contributions from Internationally-Renowned Speakers Including: The keynote lecture will be delivered by Professor Sir Anthony Coates, Professor of Medical Microbiology at St George's, University of London and Chief Scientist officer at Helperby, a spin-out of the UK’s University of London St George’s. Anthony Coates is one of the world’s foremost experts in antibiotic resistance. In addition, there will be sessions on novel therapeutic targets for anti-infective development, antibiotic discovery from natural sources, novel antibiotic discovery platforms, the SME perspective and ‘meet the funders’.. For more information, to view the programme and to register, please visit us online:. .
APS 20th Anniversary International Pharmaceutical Photostability Conference 2015
Burleigh Court, Loughborough Monday 5th - Wednesday 7th October 2015. Registration still open!. In this International Year of Light 2015, the APS is particularly pleased to be presenting this event, which will comprise a one-day workshop and a two-day conference. The course will be suitable for those who are new to the topic of pharmaceutical photostability and photostability testing and also for those who wish to brush up on the basic concepts prior to the PPS’015 conference that will follow it. The course will cover the following topics and will include opportunities to discuss the application of the concepts presented to the attendees own situations and also to network with practitioners in the field. Fundamentals of Photochemistry Kinetics and Mechanisms of Photodegradation Practical exercise to cement concepts led by experts in the field The ICH guideline on Photostability testing and sample presentation Requirements of Irradiation Chambers Measurement of Light: Radiometry, Photometry, Actinometry The impact of excipients and packaging components on photostability Photostabilisation of drugs The business of the day will conclude with a ‘brains trust’ where participants can bring issues to a panel of experts in the field. This will be followed by a drinks reception for all participants of course and conference. The course will be presented by a panel of experts in the field of photostability and photostability testing from both academia and industry including Prof Hanne Tønnesen, Dr Steve Baertschi, Dr Allen Templeton, Dr Gregory Sluggett, David Clapham and Dr Leonardo Allain.. The conference will consist of four ½ day sessions focused on specific aspects of the field with a mix of invited speakers and submitted presentations supported by a poster session. These sessions will allow an in depth consideration of each topic. In addition each day will include a breakout session facilitated by an expert leader where delegates can provide input to various topics that require discussion by the photochemistry/photostability community.. If you would like to submit an abstract for consideration, please download the abstract form here.. This event is supported by the American Association of Pharmaceutical Scientists.. To find out more and to register, please visit us online here:
Recognition for a Pharmaceutical Scientist
Gordon Muirhead, a pharmacist who is Vice President at GSK, responsible for New Product Introduction for Oral Solid Dosage Forms, was conferred with an honorary degree of Doctor of Science by De Montfort University in July in recognition of his excellent work in the field of Quality by Design of pharmaceuticals. Bill Dawson, Chair of APS and also a pharmacist, is a Pro Chancellor at De Montfort and had the pleasure of conferring the degree. In the photo Gordon is seated, Bill is far left, Professor Andy Collop, Deputy Vice Chancellor is standing, centre and Dr Simon Oldroyd, Pro Vice Chancellor and Dean of Health and Life Sciences, far right.. Bill commented “it is really good to see academic recognition for a leader in the field of QbD which has the potential to add so much value in the pharmaceutical arena. Industry has been at the forefront of this initiative at DMU and it is a strong indication of the contributions which pharmaceutical science and scientists can make to both industry and academia.”.
APS Emerging nanomedicine applications in infection, cancer and CNS targeting
A one day meeting will be held on Thursday 10th September 2015 at the East Midlands Conference Centre as part of the Nanomedicines sessions and workshop opportunities at this year’s APS 6th International PharmSci Conference 2015. The meeting is organised jointly by the APS Nanomedicines Focus Group and the British Society for Nanomedicine.. . Background to the Meeting:. This event will be of interest to all those wanting to learn more about the significant role that nanotechnology promises to play in healthcare. It aims to bring together companies and academics actively developing nanomedicines and discuss challenges that are faced the scale-up and manufacture of these products. In particularly it will provide a "deep dive" into the current advances and challenges in developing nanomedicines as products for. Infectious Diseases and Anti-Infectives. Advancements in Cancer Treatment. Nanomedicine in Neuroscience. . Meeting Format: . For those who are attending PharmSci a workshop is being held on Wednesday 9th September afternoon discussing the challenges for scale-up and manufacture of nanomedicines. You will be able to actively participate and be able to address a panel of leaders in nanomedicine technology and parenteral product development. We aim to produce a perspective/white paper based on this discussion and the sessions as whole therefore, we are keen encourage participation from many areas and perspectives on this technology. On Thursday 10th September, the meeting will concentrate on the emerging nanomedicine applications with key note speakers from Industry and academia, including Dr Rolf van Heeswijk, Prof Joan Abbott and Dr Christine Dufes, and also the opportunity to hear about KTN and UK Funding Opportunities for Nanomedicine from Dr Gabriela Juarez Martinez - KTN & Innovate UK.. . This event will provide an excellent opportunity for delegates to hear about new developments and discuss common issues, network with peers and meet technology providers. This is a very exciting area of development and we hope to raise awareness of these new technological developments and support their acceleration to commercialisation through sharing experiences.. . Once registered you can choose to attend additional the workshop on Wednesday 9th September. Accommodation can be found . . For more information and registrations, please visit us online at:.
Follow us
Upcoming Events
MIBio 2015: Stability of biopharmaceuticals – From molecular interactions to successful products
21 October 2015
APS Stimulating antimicrobial innovation
22 October 2015
APS Board Meeting
29 - 30 October 2015
APS Modulated PK Inhaled Drug Delivery workshop
5 November 2015
APS Regulatory Workshop
24 - 25 November 2015
Job Vacancies
View all Vacancies
Advertise your job vacancies
Sponsored By
Join Us

Join the academy and get discounts on events, post-nominals, latest news and more.


The Academy of Pharmaceutical Sciences
Unit Q, Troon Way Business Centre
Humberstone Lane, Leicester, LE4 9HA
Tel: 0116 274 7351
Fax: 0116 274 7365

Terms of use:
The material included on this site is provided for information purposes only, and we make no representations or warranties as to its accuracy. Before relying on this material, you should take care to verify its accuracy, taking professional advice as appropriate.